Compare Devon Energy Corp (DVN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Novo Nordisk A/S — how do they compare? Devon Energy Corp trades at $48.29 (market cap $53.81B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 3.1× Devon Energy Corp's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Novo Nordisk A/S for 116 Days on average.
| DVN | NVO | |
|---|---|---|
Market Cap | $53.81B | $165.31B |
Volume | 11,556,740 | 11,432,838 |
Sector | Energy | Health |
52-Week High | $52.07 | $63.98 |
52-Week Low | $31.74 | $35.29 |
Typical Hold Time | 136 Days | 116 Days |
Enterprise Value | $64.55B | $179.56B |
Dividend Yield | 2.62% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $48.26, up 0.79% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 10.63 and net margin of 16.67%, supported by recent earnings beats. Analyst consensus is strongly bullish with a $62.53 price target, representing 30% upside potential. Recent news highlights activist investor pressure for strategic alternatives including potential sale, while BP shows interest in acquiring Eagle Ford assets.
DVN presents compelling value with attractive valuation metrics and solid profitability. Key opportunities include potential asset sales and Permian Basin strength, while risks involve oil price volatility and execution of strategic initiatives. The stock's current valuation discount to analyst targets suggests significant upside if operational improvements materialize.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
